The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Tumor subtypes associated with prostate cancer (PCa) both as first and second primary tumors: A registry-based analysis.

Andrew  Wellen

No Relationships to Disclose

David J.  Peace

Stock and Other Ownership Interests  - Amgen; Bristol-Myers Squibb; Merck

Research Funding - Celgene; Roche; Seagen

Patents, Royalties, Other Intellectual Property - U.S. Patent # 8,557,777 B2: Methods of Treating Prostate Cancer Using Prostate Specific Antigen and Tumor Endothelial Marker Peptides. October 15, 2013. (Inst); U.S. Patent # 8,557,777 B2: Methods of Treating Prostate Cancer Using Prostate Specific Antigen and Tumor Endothelial Marker Peptides. October 15, 2013. (Inst)